Table 3.
Patient characteristics of cohort by aetiology
| Parameter | Frequency (%)/median (range) | ||||||
|---|---|---|---|---|---|---|---|
| Total (n = 323) | PHH (n = 103) | NTDs (n = 40) | Genetic (n = 45) | Congenital (n = 62) | Others (n = 73) | p value | |
| Female | 137 (42.4%) | 37 (35.9%) | 17 (42.5%) | 22 (48.9%) | 27 (43.5%) | 34 (46.6%) | 0.54 |
| Male | 186 (57.6%) | 66 (64.1%) | 23 (57.5%) | 23 (51.1%) | 35 (56.5%) | 39 (53.4%) | |
| Gestational age (weeks) | 37.00 (23.29–42.14) | 27.00 (23.29–35.29) | 38.07 (33.00–40.86)* | 38.00 (29.57–41.43)* | 38.71 (30.00–42.14)* | 39.00 (27.29–42.00)* | < 0.01 |
| Preterm | 150 (46.4%) | 103 (100.0%) | 8 (20.0%)* | 14 (31.1%)* | 18 (29.0%)* | 7 (9.6%)* | < 0.01 |
| Birthweight (g) |
n = 275 2640 (525–4684) |
n = 97 904 (530–2754) |
n = 36 2880 (1760–4500)* |
n = 40 2937.5 (525–4328)* |
n = 44 3210 (1040–4600)* |
n = 58 3249 (1060–4684)* |
< 0.01 |
| Papile grade: | n = 92 | ||||||
| Grade I | 7 (7.6%) | ||||||
| Grade II | 10 (10.9%) | ||||||
| Grade III | 25 (27.2%) | ||||||
| Grade IV | 50 (54.3%) | ||||||
| TNP˟: | 61 (18.9%) | 42 (40.8%) | 2 (5.0%)* | 2 (4.4%)* | 2 (3.2%)* | 13 (17.8%)* | < 0.01 |
| VSGS | 35 (10.8%) | 35 (34.0%) | 0 (0.0%)* | 0 (0.0%)* | 0 (0.0%)* | 0 (0.0%)* | < 0.01 |
| VAD | 13 (4.0%) | 8 (7.8%) | 0 (0.0%) | 1 (2.2%) | 2 (3.2%) | 2 (2.7%) | 0.28 |
| EVD | 23 (7.1%) | 7 (6.8%) | 2 (5.0%) | 1 (2.2%) | 1 (1.6%) | 12 (16.4%) | 0.01 |
p values were obtained using the following: chi-squared test: sex, preterm, TNP; Fisher’s exact test: VSGS, VAD, EVD; Kruskal–Wallis test: gestational age, birthweight
PHH post-haemorrhagic hydrocephalus, NTDs neural tube defects, TNP temporising neurosurgical procedure, VSGS ventriculosubgaleal shunt, VAD ventricular access device, EVD external ventricular drain
˟Percentages do not add up as some infants had multiple temporising interventions
*Parameters that are statistically significant between that aetiology group and PHH